Clinical Trials · NCT07496463
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
- Phase
- Phase 2
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 1
- Start date
- Jul 2026
- Locations
- 1 site, United States
- Primary endpoint
- Greater than or Equal to 5% Weight loss